Phase II study of vinorelbine and ifosfamide in anthracycline resistant metastatic breast cancer

The new combination of ifosfamide and vinorelbine was evaluated in a phase II study of patients with metastatic breast cancer. All the patients had evaluable or measurable lesions resistant to the combination of cyclophosphamide, epidoxorubicin and 5-fluorouracil. Out of 25 patients entered the tria...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer research and treatment 1997-01, Vol.42 (2), p.183
Hauptverfasser:	Pronzato, P, Queirolo, P, Landucci, M, Vaira, F, Vigani, A, Gipponi, M, Cafiero, F
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibiotics, Antineoplastic - pharmacology Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast Neoplasms - drug therapy Drug Administration Schedule Drug Resistance, Multiple Drug Resistance, Neoplasm Female Humans Ifosfamide - administration & dosage Middle Aged Neoplasm Metastasis Vinblastine - analogs & derivatives Vinblastine - pharmacology Vinorelbine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The new combination of ifosfamide and vinorelbine was evaluated in a phase II study of patients with metastatic breast cancer. All the patients had evaluable or measurable lesions resistant to the combination of cyclophosphamide, epidoxorubicin and 5-fluorouracil. Out of 25 patients entered the trial, 7 achieved an objective response (28%) (95% C.I. 12-49.3). Ten patients (40%) experienced stable disease and the remaining patients (30%) progressive disease. The median time to progression was 4 months (range 2-12+). The activity of the ifosfamide-vinorelbine combination has been demonstrated and the toxicity was acceptable.
ISSN:	0167-6806